1750 related articles for article (PubMed ID: 27338353)
1. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
Sarkar S; Raymick J; Imam S
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
[TBL] [Abstract][Full Text] [Related]
2. The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.
Baluchnejadmojarad T; Eftekhari SM; Jamali-Raeufy N; Haghani S; Zeinali H; Roghani M
Exp Gerontol; 2017 Dec; 100():70-76. PubMed ID: 29107062
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
5. Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress.
Nataraj J; Manivasagam T; Thenmozhi AJ; Essa MM
Nutr Neurosci; 2016 Jul; 19(6):237-46. PubMed ID: 25730317
[TBL] [Abstract][Full Text] [Related]
6. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A
Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
9. ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.
Singh S; Mishra A; Shukla S
Mol Neurobiol; 2016 Sep; 53(7):4286-301. PubMed ID: 26223802
[TBL] [Abstract][Full Text] [Related]
10. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
Rai SN; Yadav SK; Singh D; Singh SP
J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
[TBL] [Abstract][Full Text] [Related]
11. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease.
Kim M; Cho KH; Shin MS; Lee JM; Cho HS; Kim CJ; Shin DH; Yang HJ
Int J Mol Med; 2014 Apr; 33(4):870-8. PubMed ID: 24535622
[TBL] [Abstract][Full Text] [Related]
12. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
[TBL] [Abstract][Full Text] [Related]
13. [Future drug targets for Parkinson's disease].
Hirsch EC
Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
[TBL] [Abstract][Full Text] [Related]
14. Current disease modifying approaches to treat Parkinson's disease.
Lindholm D; Mäkelä J; Di Liberto V; Mudò G; Belluardo N; Eriksson O; Saarma M
Cell Mol Life Sci; 2016 Apr; 73(7):1365-79. PubMed ID: 26616211
[TBL] [Abstract][Full Text] [Related]
15. Protective role of apigenin on rotenone induced rat model of Parkinson's disease: Suppression of neuroinflammation and oxidative stress mediated apoptosis.
Anusha C; Sumathi T; Joseph LD
Chem Biol Interact; 2017 May; 269():67-79. PubMed ID: 28389404
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective strategies to prevent and treat Parkinson's disease based on its pathophysiological mechanism.
Lee Y; Kim MS; Lee J
Arch Pharm Res; 2017 Oct; 40(10):1117-1128. PubMed ID: 28952032
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.
Xiong N; Long X; Xiong J; Jia M; Chen C; Huang J; Ghoorah D; Kong X; Lin Z; Wang T
Crit Rev Toxicol; 2012 Aug; 42(7):613-32. PubMed ID: 22574684
[TBL] [Abstract][Full Text] [Related]
18. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
19. Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.
Masilamoni GJ; Smith Y
J Neural Transm (Vienna); 2018 Mar; 125(3):337-363. PubMed ID: 28861737
[TBL] [Abstract][Full Text] [Related]
20. Marine-Derived Natural Compounds for the Treatment of Parkinson's Disease.
Huang C; Zhang Z; Cui W
Mar Drugs; 2019 Apr; 17(4):. PubMed ID: 30978965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
